Early Zymergen investor Jenny Rooke reflects on 'chimeras' in biotech, what it takes to spot a $500M gemHow Insmed is Pioneering the Next Frontier in Rare Disease R&DFortress Bio’s Unique Business Model Ideally Suited to Thrive in Biotech’s Bear MarketWhen is a preclinical drug worth a mother lode of cash? This top 20 list offers a few answersBristol Myers Squibb lays off 48 in New JerseyGeorge Scangos joins Voyager board in reunion with Biogen colleague Al SandrockRoche, Merck and Pfizer lead US pharma corporate reputation ranking by patient groupsAbortion providers sue FDA in a Virginia federal court over mifepristone restrictionsPerkinElmer life science and diagnostics spinoff reveals new name and brand identityAs Zynlonta sales disappoint, ADC Therapeutics cuts staff and preclinical programs